Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...

Markets have hardly recovered from the DeepSeek shock and have just met trade tariff headwinds. Nonetheless, these stocks are ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

Markets have hardly recovered from the DeepSeek shock and have just met trade tariff headwinds. Nonetheless, these stocks are ...

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments.